The CAPItello-280 study (NCT05348577) was investigating Truqap in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in p ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

Also Read: European Drug Regulator Approves AstraZeneca’s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings The PFS improvement was seen across all pre-specified patient subgroups ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

A new commercial for AstraZeneca’s Truqap ... breast cancer who have experienced recurrence or progression on other treatments. The approval was based on study data showing that the drug combo ...

AstraZeneca ... cancer charities. The medicine has been found to double the life expectancy for terminal breast cancer patients. However, Nice ruled that Enhertu did not offer value for money. The ...

AstraZeneca has ... was investigating the drug in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer (TNBC).